Range Financial Group LLC Takes $994,000 Position in Exelixis, Inc. (NASDAQ:EXEL)

Range Financial Group LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 29,855 shares of the biotechnology company’s stock, valued at approximately $994,000.

Other large investors have also modified their holdings of the company. Hsbc Holdings PLC grew its holdings in Exelixis by 45.3% in the 2nd quarter. Hsbc Holdings PLC now owns 90,211 shares of the biotechnology company’s stock worth $2,031,000 after buying an additional 28,126 shares in the last quarter. Farallon Capital Management LLC grew its stake in shares of Exelixis by 1.6% in the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock worth $608,993,000 after purchasing an additional 424,000 shares in the last quarter. Seizert Capital Partners LLC increased its holdings in shares of Exelixis by 8.0% during the third quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock valued at $12,195,000 after purchasing an additional 34,875 shares during the period. Los Angeles Capital Management LLC raised its stake in shares of Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after purchasing an additional 991,494 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Exelixis by 60.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock worth $1,424,000 after purchasing an additional 20,641 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Trading Up 3.0 %

NASDAQ EXEL traded up $1.01 during trading on Tuesday, reaching $34.21. 2,441,349 shares of the company’s stock were exchanged, compared to its average volume of 1,907,130. The firm has a market capitalization of $9.77 billion, a PE ratio of 21.93, a P/E/G ratio of 0.89 and a beta of 0.53. Exelixis, Inc. has a fifty-two week low of $19.20 and a fifty-two week high of $36.97. The company’s fifty day simple moving average is $34.67 and its 200-day simple moving average is $28.54.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The business had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. During the same period in the previous year, the company posted $0.10 EPS. Exelixis’s revenue was up 14.3% on a year-over-year basis. Equities analysts forecast that Exelixis, Inc. will post 1.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EXEL has been the subject of a number of research analyst reports. Guggenheim upped their price target on shares of Exelixis from $33.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday. Truist Financial increased their price target on Exelixis from $33.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. HC Wainwright reissued a “buy” rating and issued a $29.00 price objective on shares of Exelixis in a research note on Wednesday, September 18th. BMO Capital Markets cut Exelixis from an “outperform” rating to a “market perform” rating and raised their target price for the company from $36.00 to $40.00 in a research note on Friday, December 20th. Finally, Bank of America cut shares of Exelixis from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $35.00 to $39.00 in a research report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Exelixis currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

Insider Transactions at Exelixis

In other Exelixis news, EVP Dana Aftab sold 96,986 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $35.00, for a total transaction of $3,394,510.00. Following the transaction, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at $17,463,075. This represents a 16.27 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Patrick J. Haley sold 41,588 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $34.36, for a total value of $1,428,963.68. Following the transaction, the executive vice president now owns 288,665 shares in the company, valued at approximately $9,918,529.40. This trade represents a 12.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 314,736 shares of company stock valued at $10,849,110 in the last three months. Corporate insiders own 2.85% of the company’s stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.